Slide 1: FY22 Results & Business Update
For personal use only INVESTOR PRESENTATION FY22 RESULTS & BUSINESS UPDATE 31 AUGUST, 2022 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC 1
Slide 2: Executive Summary
EXECUTIVE SUMMARY Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on For personal use only developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases • Two commercially available oral immunotherapeutic products –
Slide 3: CEO Update & Corporate Snapshot
CEO UPDATE & CORPORATE SNAPSHOT • Refreshed the executive team, bringing on Steven Financial Snapshot For personal use only Lydeamore as CEO and Joanne Casey as R&D Manager Shares on Issue 227,798,346 • Steven brings over 30 years’ of experience in the pharmaceutical industry including over 10 years
Slide 4: Addressable Market & Industry Overview
ADDRESSABLE MARKET & INDUSTRY OVERVIEW Billion Dollar Market Travelers diarrhea treatment For personal use only market is large and growing at a Immuron’s products are a subset of the global digestive health ~$15b+ market, which a multi-billion-dollar market* CAGR of ~7% Travelers diarrhea treatment
Slide 5: Technology Platform
TECHNOLOGY PLATFORM For personal use only Immuron’s proprietary technology platform combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can b
Slide 6: Status of Product Portfolio and Key Milestones
STATUS OF PRODUCT PORTFOLIO AND KEY MILESTONES For personal use only Immuron’s Clinical Programs • The business is completing an assessment of the entire product Compound or Indication Phase Phase Phase Market portfolio, target markets, competitive advantage and, key growth brand name I II III drive
Slide 7: Distribution Capability
DISTRIBUTION CAPABILITY For personal use only Australia USA Canada Retail Pharmacy B2B E-commerce Established Developing Key Commentary • The Australian retail network includes over 3,500 pharmacies • In the USA, the key B2B customer is Passport Health - the largest network of travel clinics • We ar
Slide 8: Profit & Loss
PROFIT & LOSS For personal use only $000s Key Commentary Profit & Loss FY22* FY21 Var % Australian Sales $ 201 $ 40 404% 1• Strong rebound in global sales – up 425% on pcp – driven by the rebound in international travel Rest of World Sales $ 564 $ 106 433% ‒ Note: total revenue in FY20 was over $2.5
Slide 9: Balance Sheet
BALANCE SHEET For personal use only $000s Key Commentary Balance Sheet 30-Jun-22 30-Jun-21 1 Cash & Cash Equivalents $ 22,110 $ 25,047 1• Immuron is well funded with over $22.1m in cash & cash Receivables $ 663 $ 335 equivalents Inventories $ 327 $ 293 2• Trade and other payables rise with the incre
Slide 10: Business Positioned for Organic Growth and New M&A Strategy
BUSINESS POSITIONED FOR ORGANIC GROWTH AND NEW M&A STRATEGY For personal use only Organic Growth Strategy M&A Strategy • Focus on commercialised products and near- • By pursuing growth through M&A of a fragmented market, term development extensions, including: IMC believes that it will be able to in
Slide 11: Key Milestones Anticipated to Drive Value
KEY MILESTONES ANTICIPATED TO DRIVE VALUE For personal use only 2H 1H 2H 1H 2022 2023 2023 2024 • File IND1 for single dose • Initiate ETEC IMM-124E • Topline results for IMM- Travelan® IMM-124E per day ETEC2 CHIM3 clinical trial 124E ETEC CHIM clinical challenge clinical trial trial • Submit Comple
Slide 12: Thank You
For personal use only THANK YOU 12
Slide 13: Scientific References
SCIENTIFIC REFERENCES Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: For personal use only to 90% of volunteers 10.3109/00365521.2011.574726 Travelan as a broad Spe